Duchenne muscular dystrophy (DMD) is a recessive disease caused by a dystrophin gene mutation. Myoblast transplantation permits the introduction of the dystrophin gene into dystrophic muscle fibers. However, this strategy has so far produced limited results. Modulation of transforming growth factor-β (TGF-β) superfamily signaling promotes skeletal muscle differentiation and growth and myogenic regeneration. We investigated the possibility that the combination of TGF-β superfamily signaling inhibition with myoblast transplantation might be an effective therapeutic approach in dystrophin-deficient patients. In vitro, blocking myostatin and other ligands with a soluble form of the extracellular domain of the activin IIB receptor (ActRIIB/Fc) upregulated the expression of myogenic differentiation factors and increased human myoblast fusion. In vivo, systemic inhibition of activin IIB receptor signaling by delivery of ActRIIB/Fc increased the success of the myoblast transplantation. This effect was further increased by forcing the mice to swim weekly to induce cycles of muscle degeneration and regeneration. Treatment of dystrophic mice with ActRIIB/Fc led to increased body weight, increased skeletal muscle mass, and improved myoblast transplantation. Thus, ActRIIB/Fc represents an effective therapeutic strategy for muscular dystrophies, and its effects are enhanced when combined with muscle exercise.
INTRODUCTION
reduce fibrosis (24) . A particularly attractive strategy is the inhibition of transforming growth factor-β (TGF-β) signaling pathways. TGF-β superfamily members, includ-Duchenne muscular dystrophy (DMD) is a severe degenerative disorder of skeletal and cardiac muscles ing TGF-β1 and myostatin, are known to negatively regulate muscle growth (21) . Myostatin, also known as that affect ϳ1 in 3,500 male births (10). DMD patients characteristically display progressive muscle weakness, growth/differentiation factor-8 (GDF-8), is predominantly expressed in skeletal muscle tissue, where it is which begins in early childhood (9). Although the mutation in the gene encoding dystrophin responsible for secreted and circulated as a serum protein (21) . Myostatin inhibition has been shown to ameliorate the pheno-DMD is present at birth, clinical symptoms are not evident until 3-5 years of age (18) . New insights into the type of mouse models of muscular dystrophy (mdx mice), by increasing muscle growth and regeneration pathophysiology of dystrophic muscle, the identification of compensating proteins, and the discovery of new (6, 27, 37) . The mdx phenotype was caused by a point mutation (A to G) in exon 23 of the dystrophin gene. binding partners are paving the way for novel therapeutic strategies to treat this fatal muscle disease. Dystrophin
The development of myostatin inhibitors, such as follistatin (2, 22) , follistatin-related gene (15) , GDF-associ-is required for the assembly of the dystrophin-glycoprotein complex and provides a mechanically strong link ated serum protein-1 (16) , anti-myostatin antibodies (6, 35) , and the myostatin propeptide (22, 36) has offered between the cytoskeleton and the extracellular matrix.
So far there is no corrective therapy for the DMD, a multifaceted approach to the treatment of muscle degenerative diseases currently under preclinical or clin-but several potential therapies have been considered to increase muscle mass, improve muscle physiology, and ical investigation. They range from suppression of 1420 FAKHFAKH, LEE, AND TREMBLAY myostatin activity to inhibition of myostatin activation. domain. The methods for expression and purification of ActRIIB/Fc fusion protein have been previously Interestingly, Lee et al. demonstrated that a soluble version of the activin type IIB receptor (ActRIIB/Fc), described (19, 23) . which competes with the natural receptor for circulating Cell Differentiation Assay agonists of this receptor, promotes skeletal muscle growth in wild-type mice (23) . The in vivo ligands for Myoblast differentiation was evaluated by counting the percentage of nuclei inside myotubes (i.e., syncytia ActRIIB include activin, inhibin, members of the bone morphogenetic protein (BMP) family, myostatin, and with three or more nuclei). For this test, myoblasts were cultured in MB-1 for 24 h, and the proliferation medium growth and differentiation factor 11 (GDF11) (3, 34 ing only 2% FBS in the presence or absence of ActRIIB/ Fc (500 ng/ml) and of human recombinant myostatin the affinities of BMP-2 and BMP-7 for ActRIIB are lower by orders of magnitude (29) .
(500 ng/ml). Myotubes were visualized by myosin heavy chain (MyHC) immunodetection. The cells were Myoblast transplantation represents a potential approach to restore the missing dystrophin (30, 32) . However, this fixed with 95% ethanol, washed twice with phosphatebuffered saline (PBS) for 10 min, and blocked with 10% technique requires multiple close injection trajectories due to limited migration of transplanted muscle precur-FBS in PBS for 1 h. The samples were incubated 2 h at room temperature with a mouse anti-MyHC mAb sor cells (myoblasts) and their fusion only with damaged host fibers (28, 31, 33) . Several approaches have been (MF20, DSHB, Iowa City, IA, USA) (1:100) and then for 1 h with an anti-mouse Ig Alexa 546-conjugated developed to resolve these problems, among them the blockade of myostatin and homologous proteins in mdx secondary antibody (Invitrogen inc., Burlington, ON, Canada) diluted 1:100. Finally, the cells were washed mice or in normal human myoblasts by follistatin upregulation or by dnActRIIB expression. These approaches with PBS and mounted with PBS/glycerol. 4′,6-Diamidino-2-phenylindole (DAPI) staining was done with PBS increased the extent of muscle repair and improved the success of myoblast transplantation (measured by the to label the nuclei. The number of nuclei in the myotubes was counted and normalized with the total number of dystrophin-positive fibers present in mdx mouse muscles) (4, 5, 11) .
number of nuclei in the culture well as a measure of terminal differentiation. The aim of the present study was to investigate whether systemic administration of ActRIIB/Fc improves Quantitative RT-PCR the transplantation of human myoblasts.
Quantitative RT-PCR (Q-RT-PCR) was used to MATERIALS AND METHODS examine the mRNA expression levels of myogenic regu-Isolation of Human Myoblasts lator factors (MRFs) [myogenic differentiation (MyoD), myogenic factor 5 (Myf5), myogenic regulatory factor 4 Primary myoblast cultures were derived from a mus-(MRF4), and myogenin] in normal myoblasts incubated cle biopsy of the quadriceps femoris of a human cadavor not with ActRIIB/Fc (500 ng/ml) and in the presence eric donor aged 13 months following informed consent or absence of recombinant myostatin (500 ng/ml). The of the family and approval by the Human Ethic Commit-mRNA was extracted using an RNeasy Plus kit (Qiagen, tee of the Research Center Hospital of Laval University Mississauga, ON Canada). The cDNA templates for Q-(CRCHUL). The muscle samples were dissociated with RT-PCR were synthesized by an inverse transcriptase collagenase and trypsin as previously described (20) and with 1 µg RNA in superscript II RNAse H-RT reaction cultured in MB-1 growth medium (Hyclone, South (Invitrogen Inc.). Q-RT-PCR was carried out in a Light Logan, UT, USA) with 15% fetal bovine serum (FBS), Cycler 480 (Roche Diagnostics, Mississauga, ON, 1% of penicillin-streptomycin (Gibco, Burlington, Ontario, Canada) with SYBR Green light Cycler Fast Start DNA Canada), and 10 ng/ml of basic fibroblast growth factor Master Plus (Roche Diagnostics) as a detector. All target (Strathmann Biotec AG, Hamburg, Germany) in a gene expressions were normalized to glyceraldehyde 3humidified atmosphere with 5% CO 2 at 37°C. Desmin phosphate dehydrogenase (GAPDH) levels. The primer labeling and a cell viability test with trypan blue were pairs were designed with GeneTools logiciels (Biotools done before using the myoblasts for in vitro and in Inc., Madrid, Spain) and are shown in Table 1 . vivo experiments.
Animals Expression and Purification of ActRIIB/Fc
The ActRIIB/Fc is a fusion protein containing the All experiments were performed in Rag −/− /mdx mice, which were 30 days old for the first experiment and 48 extracellular domain of ActRIIB linked to a murine Fc days old for the second experiment. This stable mouse on the myoblast transplantation success. In each experiment, two groups of mice (n = 3) were treated or not line was produced in our animal facilities by crossing mdx/mdx mice (a DMD model due to a mutation leading with ActRIIB/Fc (10 mg/kg, IP). In the second experiment, to induce cycles of muscle degeneration and to dystrophin deficiency) with Rag −/− mice (an immunodeficient mouse that accepts human grafts). To establish regeneration, mice were forced to swim for 10 min on days 0, 7, 14, and 21 posttransplantation. For this swim-a stable mouse line, we crossed female homozygous mdx with male homozygous rag mice. The F1 mice ming, mice were placed inside a Plexiglass box filled with warm water (28°C). All contacts with box bottom were genotype by PCR amplification and sequencing of the dystrophin exon 23 and of the rag gene. For Rag and top were avoided. All mice were killed 30 days after the myoblast transplantation for muscle analysis. Thus, genotyping, we used the protocol described elsewhere (http://jaxmice.jax.org/protocolsdb/f?p=116:2:41187229 the four groups of mice were the following: group 1A (noSwim/noActRIIB/Fc) : mice were injected on days 0 and 7 26490498::NO:2:P2_MASTER_PROTOCOL_ID,P2_ JRS_CODE:329,003145). We crossed the F1 females posttransplantation with sterile PBS and not forced to swim; group 1B (noSwim/ActRIIB/Fc 2wk) : mice were injected on that were heterozygous mdx and heterozygous mdx with males that were mdx and heterozygous rag. In the F2 days 0 and 7 posttransplantation with ActRIIB/Fc and not forced to swim; group 2A (Swim/noActRIIB/Fc) : mice were generation, one female, which was homozygous rag and homozygous mdx (one female out of eight had this injected on days −5, 0, 7, 14, and 21 posttransplantation with sterile PBS and were forced to swim; group genotype) was crossed with a male that was homozygous rag and mdx (one male out of four had this geno-2B (Swim/ActRIIB/Fc 5wk) : mice were injected on days −5, 0, 7, 14, and 28 posttransplantation with ActRIIB/Fc and type). All the mice resulting from that cross were homozygous for rag −/− and mdx genes. The mice were were forced to swim. maintained under pathogen-free conditions. All the Muscle Morphometry experiments with mice were conducted in accordance with the Laboratory Animal Care and use Ethics Com-For measurement of muscle weights, individual TA from both sides of the animal was dissected and the mittee of Laval University.
average weight was used for each group. The muscles Cell Transplantation and ActRIIB/Fc Treatment were mounted in embedding medium and snap-frozen in liquid nitrogen. Serial 12-µm cross sections were Half a million human myoblasts resuspended in 10 µl of HBSS were transplanted at day 0 into both tibialis obtained in a cryostat at −25°C. Sections were then processed for histological examination by hematoxylin and anterior muscles (TAs) of 12 mice using a glass capillary along 12 transversal axis trajectories. All mice were eosin-phloxine staining (H&E), and by immunohistochemistry with an anti-human dystrophin antibody (7F7, sacrificed 30 days after the transplantation. Two experiments were done to evaluate the effect of ActRIIB/Fc MRIC Biochemistry Group, Wrexham, UK) and with anti-lamin A/C (Vector Laboratory, USA) to visualize myogenin ( Fig. 2c) ; however, the ActRIIB/Fc and/or rMSTN treatment did not change the expression of human nuclei as previously described (11) . Morphometric measurements (i.e., single fiber area, total number of Myf5 and MRF4 ( Fig. 2b, d ). nucleus lamin A/C, number of nuclei lamin A/C-posi-ActRIIB/Fc Long-Term Treatment Increases tive per fibers, total number of centro-nucleated fibers)
the Mouse Body Weight were made using the Image J software (rsbweb.nih.gov/ij).
Next, we examined the effect of ActRIIB/Fc follow-Statistical Analysis ing transplantation of myoblasts in vivo ( Figs. 3 and 4 ). The experimental values are presented as means ± All mice were weighed in the days 0 and 30 posttrans-SD. Statistical analyses were performed by analysis of plantation and the results are plotted in Figure 3a (Fig. 4) . Indeed, the mean per-ActRIIB/Fc Promotes the Differentiation centage increase in body weight over that time period of Human Myoblasts Even in the Presence compared to controls mice was 40% (Fig. 3b ).
of Recombinant Myostatin
ActRIIB/Fc Long-Term Treatment Accentuates The activation of satellite cells in skeletal muscle the Increase of the Muscle Weight leads to their proliferation as myoblasts and to their dif-
The TA muscles of all experimental mice were disferentiation and fusion with existing muscle fibers, sected, trimmed of excess connective tissues, and which is essential for muscle hypertrophy. Several memweighed to determine the effect of ActRIIB/Fc treatment bers of the TGF-β family inhibit myoblast differentiaon muscle mass (Fig. 3c ). The effect of ActRIIB/Fc tion. The effect of ActRIIB/Fc, which binds to several long-term treatment was evident in the weight of the members of this family, was thus evaluated on the in TA muscle, which was significantly increased in group vitro myogenic differentiation of human myoblasts in 2B (Swim/ActRIIB/Fc 5wk) . This increase was 71% when comthe presence or absence of recombinant myostatin.
pared with the TA weight of group 2A (Swim/noActRIIB/Fc) When myoblasts were transferred to a differentiation and 85% when compared with the mice of group medium in the absence of myostatin, the presence of 1A (noSwim/noActRIIB/Fc) . However, the TA weight of group ActRIIB/Fc for 3 days did not significantly increase the 1B (noSwim/ActRIIB/Fc 2wk) was increased by only 22% compared number of myotubes ( Fig. 1a ) or the fusion index ( Fig. to the TA of its control group 1A (noSwim/noActRIIB/Fc) , which 1b). The presence of myostatin alone in the differentiadid not reach statistical significance. There were no diftion medium significantly decreased the number of myoferences in muscle weights of mice in the control tubes, with the fusion index being reduced by about groups, namely group 2A (Swim/noActRIIB/Fc) versus group fivefold to 8%. However, this reduction in the number 1A (noSwim/noActRIIB/Fc) . of myotubes and the fusion index by myostatin was When TA muscle weights were expressed relative to completely blocked by the addition of ActRIIB/Fc to body mass, significant increases with ActRIIB/Fc treatthe cells. ment were observed only for group 2B (Swim/ActRIIB/Fc 5wk) Expression of MyoD Family mRNA compared to group 2A (Swim/noActRIIB/Fc) and to group in ActRIIB/Fc-Treated Myoblasts 1A (noSwim/noActRIIB/Fc) (Fig. 3d ). The magnitude of the effects was blunted after normalization to body weights, which To analyze further the effect of myostatin and ActRIIB on myoblast differentiation in these cultures, was expected given that ActRIIB/Fc has been shown previously to cause increases in muscle mass throughout we carried out Q-RT-PCR analyses of Myf5, myogenin, MRF4, and MyoD. As shown in Figure 2a , myostatin the body (23) and given that skeletal muscle accounts about one third of total body weight. and ActRIIB had opposite effects on MyoD expression, with myostatin causing a decrease and ActRIIB/Fc caus-ActRIIB/Fc Treatment Improved Success of Human ing an increase in expression levels. In cells treated with Myoblast Transplantation in Mice both myostatin and ActRIIB/Fc, the two molecules appeared to neutralize each other in their effects on Following their transplantation, human myoblasts fused with the existing mouse muscle fibers, leading to MyoD expression. Similar results were obtained with 
the expression of human dystrophin in the resulting
Swimming alone also seemed to increase the success of transplantation, as the number of dystrophin-positive hybrid fibers. To evaluate the success of the myoblast transplantation, human dystrophin was thus detected by fiber in mice in group 2A (Swim/noActRIIB/Fc) was more than double that seen in mice in group 1A (noSwim/noActRIIB/Fc) . immunohistochemistry in the four groups of mice. In group 1B (noSwim/ActRIIB/Fc 2wk) , the number of dystrophin-posi-ActRIIB/Fc and forced swimming appeared to have an additive effect, leading to a tripling of dystrophin-tive myofibers present in muscle cross sections was more than double (135 ± 26) that observed in group positive fibers in group 2B (Swim/ActRIIB/Fc 5wk) compared to group 1A (noSwim/noActRIIB/Fc) . 1A (noSwim/noActRIIB/Fc) (59 ± 23) ( Fig. 5a) . A very significant increase of the number of dystrophin-positive fibers was ActRIIB/Fc Treatment Changed the Total Number also observed in the second experiment that involved of Human Nuclei per Muscle Cross Section swimming. Specifically, the TA muscle of group 2B (Swim/ActRIIB/Fc 5wk) contained 185 dystrophin-positive To confirm that the increased muscle mass and number of dystrophin-positive fibers resulted in part from fibers per muscle cross section, which represented an increase of 77% compared to group 2A (Swim/noActRIIB/Fc) .
fusion of the transplanted myoblasts to myofibers, we muscle fiber expressing human dystrophin. All trans-ActRIIB/Fc Treatment Does Not Affect the Percentage of Centrally Nucleated Fibers planted TAs of mice contained a mixed population of fibers incorporating one or more human nuclei. In the Finally, we compared the percentage of centrally experimental groups of mice that received ActRIIB/Fc nucleated fibers in the various groups of mice. ActRIIB/ [i.e., group 1B (noSwim/ActRIIB/Fc 2wk) and group 2B (Swim/ActRIIB/Fc Fc treatment in the first experiment did not significantly 5wk) ], the percentage of fibers with only one human increase the number of centro-nucleated fibers (Fig. 7) . nucleus was lower than in their respective control However, swimming by itself increased the percentage groups that did not receive ActRIIB/Fc [i.e., group 1A (noSof centrally nucleated fibers in group 2A (Swim/noActRIIB/Fc) wim/noActRIIB/Fc) and group 2A (Swim/noActRIIB/Fc) (Fig. 6a, b . Morecompared to group 1A (noSwim/noActRIIB/Fc) . Similarly, musover, the percentage of fibers with more than three cles from group 2B (Swim/ActRIIB/Fc 5wk) contained more human nuclei was higher in muscles of ActRIIB/Fccentro-nucleated fibers than those of either group treated mice compared to muscles of untreated mice.
1A (noSwim/noActRIIB/Fc) or group 1B (noSwim/ActRIIB/Fc 2wk) .
ActRIIB/Fc Treatment Induced Dystrophin-Positive DISCUSSION Fiber Hypertrophy
We then investigated whether the inhibition of signal-Several studies have already demonstrated an increase of body and/or muscle growth in different mouse disease ing of myostatin and other TGF-β family members with ActRIIB/Fc was sufficient to trigger hypertrophy of the models after ActRIIB/Fc treatment (1, 25, 26) . Our study confirms this effect of activin receptor blockade in a dystrophin-positive fibers. As shown in Figure 6c , significant hypertrophy was observed in the hybrid muscle model of DMD. The increased skeletal muscle mass observed was due to hypertrophy and is comparable to fibers of both ActRIIB/Fc-treated groups. Specifically, group 2A (noSwim/ActRIIB/Fc 2wk) had a 70% hypertrophy relative prior studies of myostatin inhibition studies in mdx mice (7, 37) . Hypertrophy was even observed in our study in to group 1A (noSwim/noActRIIB/Fc) , and group 2B (Swim/ActRIIB/Fc 5wk) had a 350% hypertrophy compared with group the dystrophin-positive fibers resulting in part from the transplantation of normal human myoblasts into Rag −/− / 2A (Swim/ noActRIIB/Fc) . Swimming did not by itself induce a significant hypertrophy of the dystrophin-positive musmdx mice. Souza et al. demonstrated that depletion of circulating BMP-9 and BMP-10 by ActRIIB/Fc may cle fibers since group 2A (Swim/ noActRIIB/Fc) was indeed not significantly different from group 1A (noSwim/noActRIIB/Fc) .
indirectly contribute to the increase in muscle mass by maintaining a higher number of myogenic stem cells is explained by the exceptional conservation of the ActRIIB extracellular domain sequence, with only one (satellite cells) in the skeletal muscle (34). In our studies, we found the proportion of centrally nucleated amino acid difference between mouse and human (13) . Following human myoblast transplantation, the mice fibers, an indicator of regenerated fibers, to be unchanged in untreated and ActRIIB/Fc-treated TAs. treated with ActRIIB/Fc presented more dystrophinpositive myofibers and human nuclei than their respec-Thus, our observations suggest that blocking this signaling pathway did not alter regeneration in TAs of mdx tive control mice. This increase of human nuclei was more significant in group 2B (Swim/ActRIIB/Fc 5wk) . mice (25) . However, when the ActRIIB/Fc treatment was combined to exercise, the number of centrally Different cellular therapy problems were responsible for the low number of dystrophin-positive fibers observed nucleated fibers increased significantly. Moreover, forced swimming alone appears to be inducing sufficient in clinical trials; among others, at least 75% of the transplanted myoblasts die in the first 3 days after transplanta-fiber damage to cause increased regeneration.
A major finding of our study is that ActRIIB/Fc tion (12,14,17). The ActRIIB/Fc treatment increased early survival of the transplanted human myoblasts and improves the success of human myoblast transplantation by threefold as evaluated by the number of human dys-improved myoblast transplantation success. This enhanced success of myoblast transplantation trophin-positive myofibers. This improvement was the highest compared to the other studies (8,11). Our in vitro may be due to an upregulation myogenic gene expression and to increased proliferation, differentiation, and/ study indicated that ActRIIB/Fc increased the differentiation of human myoblasts through an upregulation of or fusion of the transplanted myoblasts with damaged fibers. The effect of ActRIIB/Fc on enhancing incorpo-the regulatory genes responsible for myogenesis, such as myogenin and MyoD, leading to myoblast fusion and ration of transplanted myoblasts was observed in both experimental paradigms (i.e., with or without forced myotube maturation (38). Despite its murine origin, the soluble form of the ActRIIB competed with the natural swimming). Thus, the ActRIIB/Fc treatment during the first 2 weeks after myoblast transplantation was suffi-human receptors for ligand in the TGF-β family, which includes myostatin, activin-A, and BMP9/10 (34). This cient to produce a beneficial effect on graft success, but exercise combined with a long-term ActRIIB/Fc treat-an effective therapeutic strategy for delivering normal copies of the dystrophin gene and restoring muscle func-ment further enhanced myoblast transplantation success and fiber hypertrophy. Swimming is a physiological tion to patients with DMD. method to induce partial muscle fiber damage, and our ACKNOWLEDGMENTS: We thank the AFM "association results confirm that myoblasts are able to repair damfrançaise contre les myopathies" and Jessee Journey. Work in aged myofibers, giving rise to more hybrid fibers (8). is a potential therapy for the treatment of diseases affectis entitled to a share of royalty received by the University on ing skeletal muscle, such as muscular dystrophies. Our sales of products related to myostatin. S.-J.L. and the Universtudy suggests that combining myostatin inhibition and sity own MMI stock, which is subject to certain restrictions under University policy. S-J.L., who is the scientific founder muscle exercise with myoblast transplantation may be 
